$133.62
Live
Insights on Transmedics Group Inc
Revenue is up for the last 11 quarters, 5.37M → 96.85M (in $), with an average increase of 24.5% per quarter
Netprofit is up for the last 3 quarters, -25.42M → 12.19M (in $), with an average increase of 398.8% per quarter
1.23%
Downside
Day's Volatility :3.12%
Upside
1.91%
72.74%
Downside
52 Weeks Volatility :74.75%
Upside
7.36%
Period | Transmedics Group Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 53.63% | -1.0% | 0.0% |
6 Months | 78.86% | 9.6% | 0.0% |
1 Year | 78.75% | 11.0% | 0.0% |
3 Years | 411.01% | 18.5% | -22.6% |
Market Capitalization | 4.5B |
Book Value | $4.85 |
Earnings Per Share (EPS) | -0.34 |
Wall Street Target Price | 119.2 |
Profit Margin | -3.43% |
Operating Margin TTM | 12.83% |
Return On Assets TTM | 1.85% |
Return On Equity TTM | -5.79% |
Revenue TTM | 296.9M |
Revenue Per Share TTM | 9.1 |
Quarterly Revenue Growth YOY | 133.1% |
Gross Profit TTM | 65.3M |
EBITDA | 26.2M |
Diluted Eps TTM | -0.34 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.75 |
EPS Estimate Next Year | 1.01 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.04 |
What analysts predicted
Downside of 10.79%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 13.0M | ↑ 69.38% |
Net Income | -23.8M | ↑ 14.09% |
Net Profit Margin | -182.5% | ↑ 88.46% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 23.6M | ↑ 81.33% |
Net Income | -33.5M | ↑ 41.21% |
Net Profit Margin | -142.12% | ↑ 40.38% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 25.6M | ↑ 8.62% |
Net Income | -28.7M | ↓ 14.31% |
Net Profit Margin | -112.13% | ↑ 29.99% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 30.3M | ↑ 18.03% |
Net Income | -44.2M | ↑ 53.8% |
Net Profit Margin | -146.11% | ↓ 33.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 93.5M | ↑ 208.83% |
Net Income | -36.2M | ↓ 18.06% |
Net Profit Margin | -38.77% | ↑ 107.34% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 241.6M | ↑ 158.53% |
Net Income | -25.0M | ↓ 30.92% |
Net Profit Margin | -10.36% | ↑ 28.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.4M | ↑ 22.16% |
Net Income | -6.7M | ↓ 9.51% |
Net Profit Margin | -21.42% | ↑ 7.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.6M | ↑ 32.44% |
Net Income | -2.6M | ↓ 60.77% |
Net Profit Margin | -6.34% | ↑ 15.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 52.5M | ↑ 26.26% |
Net Income | -1.0M | ↓ 62.03% |
Net Profit Margin | -1.91% | ↑ 4.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.4M | ↑ 26.62% |
Net Income | -25.4M | ↑ 2439.66% |
Net Profit Margin | -38.27% | ↓ 36.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.2M | ↑ 22.19% |
Net Income | 4.0M | ↓ 115.86% |
Net Profit Margin | 4.97% | ↑ 43.24% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 96.9M | ↑ 19.31% |
Net Income | 12.2M | ↑ 202.58% |
Net Profit Margin | 12.59% | ↑ 7.62% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 42.2M | ↑ 13.93% |
Total Liabilities | 47.0M | ↓ 77.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 105.3M | ↑ 149.78% |
Total Liabilities | 50.7M | ↑ 7.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 152.0M | ↑ 44.38% |
Total Liabilities | 48.1M | ↓ 4.97% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 134.9M | ↓ 11.27% |
Total Liabilities | 67.0M | ↑ 39.27% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 277.1M | ↑ 105.46% |
Total Liabilities | 89.8M | ↑ 33.91% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 706.0M | ↑ 154.76% |
Total Liabilities | 568.8M | ↑ 533.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 277.1M | ↑ 0.83% |
Total Liabilities | 89.8M | ↑ 3.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 287.1M | ↑ 3.59% |
Total Liabilities | 94.5M | ↑ 5.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 690.4M | ↑ 140.47% |
Total Liabilities | 545.1M | ↑ 477.1% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 689.2M | ↓ 0.16% |
Total Liabilities | 562.8M | ↑ 3.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 706.0M | ↑ 2.44% |
Total Liabilities | 568.8M | ↑ 1.08% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 723.8M | ↑ 2.52% |
Total Liabilities | 564.4M | ↓ 0.79% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.0M | ↑ 12.49% |
Investing Cash Flow | 12.3M | ↓ 50.49% |
Financing Cash Flow | 22.1M | ↑ 735366.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.3M | ↑ 24.25% |
Investing Cash Flow | -60.5M | ↓ 591.6% |
Financing Cash Flow | 92.7M | ↑ 320.25% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -30.3M | ↓ 6.26% |
Investing Cash Flow | -41.6M | ↓ 31.24% |
Financing Cash Flow | 75.5M | ↓ 18.52% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.9M | ↓ 4.63% |
Investing Cash Flow | 29.3M | ↓ 170.36% |
Financing Cash Flow | 1.4M | ↓ 98.16% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -45.8M | ↑ 58.73% |
Investing Cash Flow | 54.5M | ↑ 86.26% |
Financing Cash Flow | 167.9M | ↑ 11955.06% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.0M | ↓ 71.75% |
Investing Cash Flow | -2.8M | ↓ 111.17% |
Financing Cash Flow | 3.1M | ↓ 98.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.7M | ↑ 114.65% |
Investing Cash Flow | -927.0K | ↓ 66.46% |
Financing Cash Flow | 4.0M | ↑ 29.14% |
Sell
Neutral
Buy
Transmedics Group Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Transmedics Group Inc | 0.74% | 78.86% | 78.75% | 411.01% | 378.1% |
Stryker Corporation | 4.27% | 16.65% | 22.1% | 34.77% | 82.03% |
Boston Scientific Corp. | 4.07% | 37.85% | 46.89% | 79.63% | 93.34% |
Edwards Lifesciences Corp. | 3.26% | 27.0% | 2.23% | -8.36% | 51.45% |
Abbott Laboratories | -2.62% | -2.21% | -0.86% | -5.87% | 32.8% |
Medtronic Plc | 0.44% | 2.96% | -1.92% | -33.69% | -13.02% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Transmedics Group Inc | NA | NA | NA | 0.75 | -0.06 | 0.02 | NA | 4.85 |
Stryker Corporation | 38.89 | 38.89 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.5 | 63.5 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 37.45 | 37.45 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 31.83 | 31.83 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 29.48 | 29.48 | 1.52 | 5.2 | 0.07 | 0.04 | 0.03 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Transmedics Group Inc | Buy | $4.5B | 378.1% | NA | -3.43% |
Stryker Corporation | Buy | $129.9B | 82.03% | 38.89 | 16.03% |
Boston Scientific Corp. | Buy | $111.1B | 93.34% | 63.5 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | 51.45% | 37.45 | 23.01% |
Abbott Laboratories | Buy | $177.8B | 32.8% | 31.83 | 13.96% |
Medtronic Plc | Buy | $106.7B | -13.02% | 29.48 | 11.36% |
FMR Inc
BlackRock Inc
Vanguard Group Inc
Macquarie Group Ltd
Driehaus Capital Management LLC
Amvescap Plc.
Transmedics Group Inc’s price-to-earnings ratio stands at None
Read Moretransmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Organization | Transmedics Group Inc |
Employees | 584 |
CEO | Dr. Waleed H. Hassanein M.D. |
Industry | Medical Specialties |
Slm Corp
$133.62
-0.01%
Rocket Lab Usa Inc
$133.62
-0.01%
Harley-davidson, Inc.
$133.62
-0.01%
Grupo Aeroportuario Del Sureste, Sabdecv
$133.62
-0.01%
Ishares Msci Min Vol Global Etf
$133.62
-0.01%
Surgery Partners Inc
$133.62
-0.01%
Taiwan Msci Etf Ishares
$133.62
-0.01%
Vail Resorts Inc.
$133.62
-0.01%
Uipath, Inc.
$133.62
-0.01%